cardiovascular drug
DESCRIPTION
clinical cardiovascular drugsTRANSCRIPT
DigoxinInhibition of sacrolemmal Na+K+-ATPaseEnhanced Vagal Tone
GI : Nausea, VomitingCardiac : atrial, nodal, and ventricular tachyarrhythmias; high-degree AV block
Dopamine Low dosage (< 2 g/kg/m): D1 receptor stimulation mesenteric & renal arterial dilatation (facilitates diuresis)Medium dosage (2 -10 g/kg/m): 1 receptor stimulation & release of norepinephrine from sympathetic nerve terminals (inotropic effect)Tachycardia, arrhythmias, hypertension40 mg/mL (in 5 mL)in 100 mL NS200 mg in 105 mL mixed : 1,9 mg/mLmicroinfusion : 30 g/drop
Starting dose at 2 g/kg/m, increase gradually 5 10 g/kg/m
In 70 kg person140 g/m 140/30 = 4,6 = 5 drop/m5 g/m 11,6 = 12 drop/mWith Syringe 8,4 mg/h = 4.4 ml/h
Dobutamine1-, 2- and - receptor stimulation
tachyarrhythmias50 mg/mL (in 5 mL)in 100 mL NS250 mg in 105 mL mixed : 2,3 mg/mLmicroinfusion : 38 g/drop
Starting dose at 0,5 g/kg/m, increase graduallyMax 40 g/kg/m
In 70 kg person35 g/m 35 / 40 =0,87= 1 drop/mwith syringe 0.87 ml/hr
Norepinephrine1- and - receptor stimulationTachyarrhytmias1 mg/mL (in 4 mL)in 1000 D5% or NS
Starting dose 0,05 g/kg/m
Nicardipine